Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Month, Single Blind, Placebo Controlled, Phase III Study to Assess the Effects of Enclomiphene Citrate Treatment On Bone Mineral Density in Men With Secondary Hypogonadism

NCT01619683 is registered in ClinicalTrials.gov with Repros Therapeutics Inc. as lead sponsor.

NCT NCT01619683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01619683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Month, Single Blind, Placebo Controlled, Phase III Study to Assess the Effects of Enclomiphene Citrate Treatment On Bone Mineral Density in Men With Secondary Hypogonadism
Lead sponsor
Repros Therapeutics Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2012
Completion date
September 30, 2014
Enrollment
300 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

effect of treatment on bone mineral density